Navigation Links
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Date:4/15/2008

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today interim results from two ongoing Phase 1 trials in hormone refractory prostate cancer (HRPC) demonstrating dose-dependent T-cell activation and clinical activity of ipilimumab, an investigational anti-CTLA-4 antibody. These studies were done in combination with antigen-releasing immunotherapies based on GM-CSF, a cytokine that stimulates the proliferation of white blood cells and augments immune responses, and results were presented in two separate oral presentations by investigators at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego.

"The interim results demonstrating clinical activity in these ongoing trials lend additional support to the concept of ipilimumab as part of a therapeutic regimen in treating prostate cancer," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We will continue to explore the prospects of ipilimumab in HRPC, and we expect further data in prostate cancer for ipilimumab monotherapy and in combination with other antigen-releasing agents at this year's ASCO conference in June."

-- "Dendritic and T cell functions in patients with metastatic

hormone-refractory prostate cancer treated with GVAX immunotherapy for

prostate cancer and ipilimumab" (Abstract #2538)

Interim data from the ongoing Phase 1 study of escalating doses of

ipilimumab in combination with the Cell Genesys, Inc. GVAX

immunotherapy for prostate cancer (an investigational agent comprised

of whole tumor cells modified to secrete GM-CSF) were presented by

Saskia JA
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014  ADM Tronics Unlimited, Inc. ... Ph.D. to its corporate Advisory Board for business ... at the Harvard Medical School and Visiting Professor ... received his Masters degree in Electronics Engineering and ... University of Bologna. After spending a year as ...
(Date:9/18/2014)... Sept. 18, 2014 MiMedx Group, Inc. ... processor and marketer of patent protected regenerative biomaterials ... today that it has entered into a distribution ... will provide its dehydrated human amnion/chorion membrane ("dHACM") ... exclusively on a private label basis. ...
(Date:9/18/2014)... and PLAINSBORO, N.J. , ... its support of the National Hemophilia Foundation,s (NHF) ... which provides support to people with hemophilia and ... psychosocial challenges that can impede disease management. The ... Communication With Your Provider About Pain , ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... survival,in the SPARC Phase 3 trial consistently demonstrate ... patients receiving,satraplatin. These analyses included prior Taxotere use,geographies, ... -- The two,major causes of progression in the ... were each associated with a 36%,reduction in relative ...
... co-primary endpoints, Wake After Sleep Onset and Total,Sleep Time, ... met at both doses - Evotec to host a,conference ... today , HAMBURG, Germany | OXFORD, England, June 4, ... top-line,results from its first phase II clinical trial of ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4
(Date:9/18/2014)... Alan Mozes HealthDay ... When it comes to emergency room waiting times, patients seeking ... time staring down the clock than those seen at smaller ... of crowding and our ability to provide timely emergency care ... of the authors of the new research, Dr. Renee Hsia, ...
(Date:9/18/2014)... proven it true: exercise is good for you. But ... exercise may have an added benefit for cancer patients ... model of melanoma, found that combining exercise with chemotherapy ... Libonati, an associate professor in the School of Nursing ... Nursing Research, was the senior author on the study, ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading strategic ... co-founder John Cassimatis was named as one of ... recognizing the region’s top healthcare and life science ... the year. , The Innovation Awards celebrate companies ... to shape the medical industry in Greater Philadelphia ...
(Date:9/18/2014)... Savannah, GA (PRWEB) September 18, 2014 ... awarded the Alex Ormond, Jr. Leadership Award by the ... toward improving healthcare and wellness throughout the nation and ... to receive this award,” said Ben. “The Savannah Science ... for 65 years and multiple generations have gone through ...
(Date:9/18/2014)... group of international scientists have developed a new method ... here . , The Wildlife Conservation Society (WCS)-led research, ... Diseases , describes the use of fecal samples from ... been exposed to the virus. This represents a new ... potentially change the way Ebola virus is studied and ...
Breaking Medicine News(10 mins):Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3
... such as having trouble remembering recent events may indicate ... than typical age-related changes. These findings, which are published ... Society, indicate that primary care clinicians, who are ... about their memory, should be aware that such complaints ...
... SEATTLE The number of cases and deaths from breast ... the developing world where more women are dying at younger ... for Health Metrics and Evaluation (IHME) at the University of ... in just three decades, from 641,000 cases in 1980 to ...
... 14, 2011, advance online edition of the New ... hepatitis C who took a combination medicationa telaprevir-based regimen ... weeks were cured. Usually, the treatment is administered ... treatment is unnecessary, possibly changing the standard of care ...
... , WEDNESDAY, Sept. 14 (HealthDay News) -- How ... much you consume in determining the risk of heart ... binge drinking, defined as having seven drinks a day for two ... increased risk for atherosclerosis or "hardening of the arteries" caused by ...
... Alan Mozes HealthDay Reporter , WEDNESDAY, Sept. ... cluster of factors known as the "metabolic syndrome" could ... obese patients without such factors, new research suggests. ... -- increased blood pressure, higher-than-normal insulin levels, excess body ...
... 14 (HealthDay News) -- Some children are born with natural ... Johns Hopkins University researchers tested the "number sense" of ... tests included having the kids look at groups of ... guess which group had more dots. Kids were also ...
Cached Medicine News:Health News:Some memory complaints in the elderly may be warning signs of cognitive problems 2Health News:More women dying from breast and cervical cancer at a younger age in developing countries 2Health News:More women dying from breast and cervical cancer at a younger age in developing countries 3Health News:Shorter treatment with hepatitis C drug combination may be more beneficial, study shows 2Health News:Drinking Patterns Affect Heart Health, Mouse Study Finds 2Health News:Drinking Patterns Affect Heart Health, Mouse Study Finds 3Health News:Certain Risk Factors Could Spur Heart Failure in Normal-Weight People 2Health News:Certain Risk Factors Could Spur Heart Failure in Normal-Weight People 3Health News:Certain Risk Factors Could Spur Heart Failure in Normal-Weight People 4Health News:Trouble With Math? Blame Your Lack of 'Numbers Sense' 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: